Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $15.78: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. (Note: Risk dimension 2.4/10 and A.R:R 2.4:1 are different metrics that happen to read the same number here.)
Amylyx is a clinical-stage pharmaceutical company developing avexitide (a GLP-1 receptor antagonist) for post-bariatric hypoglycemia, with Phase 3 LUCIDITY trial fully enrolled and topline data expected Q3 2026 for a potential 2027 commercial launch. The company withdrew its ALS... Read more
Sell if holding. Engine safety override at $15.78: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. (Note: Risk dimension 2.4/10 and A.R:R 2.4:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductavexitide10-K Item 1A: 'We currently depend heavily on the success of avexitide, our most advanced product candidate, and AMX0035.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.78: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. (Note: Risk dimension 2.4/10 and A.R:R 2.4:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $14.67. Score 4.9/10, moderate confidence.
Take-profit target: $20.27 (+28.5% upside). Prior stop was $14.67. Stop-loss: $14.67.
Concentration risk — Product: avexitide; Quality below floor (1.4 < 4.0); Value-trap signals (2/5): High leverage (D/E 7.8), Material insider selling (14 sells, 0.15% of cap).
Amylyx Pharmaceuticals, Inc. trades at a P/E of N/A (forward -12.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover AMLX with a consensus score of 4.3/5. Average price target: $23.
What does Amylyx Pharmaceuticals, Inc. do?Amylyx is a clinical-stage pharmaceutical company developing avexitide (a GLP-1 receptor antagonist) for post-bariatric...
Amylyx is a clinical-stage pharmaceutical company developing avexitide (a GLP-1 receptor antagonist) for post-bariatric hypoglycemia, with Phase 3 LUCIDITY trial fully enrolled and topline data expected Q3 2026 for a potential 2027 commercial launch. The company withdrew its ALS drug RELYVRIO in 2023 after a Phase 3 failure and has no approved products or revenue.